Prostate cancer treatment reduced from 37 treatments to 5
13 August 2018 | By Iqra Farooq (European Pharmaceutical Review)
A minimally invasive hydrogel technology was administered, and has previously shown to decrease treatment side effects...
List view / Grid view
Prostate cancer
Immunotherapy drug could boost hormone treatment for prostate cancer
29 June 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Researchers believe the combination with established treatment could improve outcomes in prostate cancer...
Contrast-enhanced subharmonic imaging detects prostate cancers
17 April 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
A test of contrast-enhanced subharmonic imaging has shown promise in detecting prostate cancers that were not identified by MRI...
Researchers to investigate screening for prostate cancer using MRI
6 April 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
A new clinical study will test for the first time if MRI scans can be used for population screening to detect prostate cancer more accurately...
Taking a standard prostate cancer drug with food boosts impact
3 April 2018 | By European Pharmaceutical Review
By taking Zytiga with a low-fat meal could decrease the daily dose and prevent digestive issues...
Acoustic Cluster Therapy drives drug therapies to cancer cells
21 March 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Researchers are testing the use of pulsed sound waves to direct and focus cancer drug therapies...
Copper PET imaging detects early recurrence of prostate cancer
6 March 2018 | By European Pharmaceutical Review
An Italian study demonstrates that copper accumulation in tumours can detect prostate cancer recurrence early in patients with biochemical relapse...
Dietary fat, changes in fat metabolism may promote prostate cancer metastasis
16 January 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Researchers have shed new light on the genetic mechanisms that promote metastasis and implicated the typical Western high-fat diet as a key environmental factor...
Shorter treatment course better for intermediate risk prostate cancer?
5 December 2017 | By European Pharmaceutical Review
New research suggests that treatment with a shorter course of radiation using higher doses over fewer days may be the preferred approach for some men with intermediate-risk prostate cancer.
EC extends license for Zytiga to treat early stage prostate cancer
22 November 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
The EC has granted approval to broaden the existing marketing authorisation for Zytiga to include early stage metastatic prostate cancer...
Tapeworm drug fights prostate cancer
16 November 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
A Norwegian study shows that NTZ contains a substance that can kill prostate and colon cancer...
Q BioMed to commercialise non-narcotic metastatic cancer pain drug
12 June 2017 | By Niamh Marriott (European Pharmaceutical Review)
Q BioMed Inc has initiated production of Strontium-89 Chloride, a radiopharmaceutical indicated for the analgesic treatment of metastatic breast and prostate cancer bone pain.
Merrimack initiates Phase 1 study of MM-310 in solid tumours
29 March 2017 | By Niamh Marriott, Junior Editor
Merrimack Pharmaceuticals have enrolled its first patient in a Phase 1 study of MM-310 in solid tumours.
Panacea initiates Phase I prostate cancer vaccine therapy trial
19 January 2017 | By Niamh Marriott, Digital Editor
Panacea Pharmaceuticals have enrolled and dosed the first patient in the open-label, parallel designed, multi-centre Phase I clinical trial of PAN-301-1, for the treatment of persistent prostate cancer to assess safety and immunogenicity. Clinical sites for the PAN-301-1 trial are located in Alabama, California, Nebraska and South Carolina and the…
NICE says ‘yes’ to degarelix for men with prostate cancer and spinal metastases
1 July 2016 | By Victoria White, Digital Content Producer
NICE has recommended Ferring’s Firmagon (degarelix) for men with advanced-hormone dependent prostate cancer and spinal metastases...
Follow: